Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints
Rather than damaging the use of progression-free survival as an endpoint in oncology clinical trials, as some have feared, the battle over Avastin’s (bevacizumab) metastatic breast cancer claim could give sponsors some clarity as to how FDA expects the magnitude of PFS benefit to be defined.
You may also be interested in...
Trailblazer Sandra Horning Is Helping Companies Break New Ground
Roche’s former chief medical officer has new career as board member to three companies, including COVID-19 vaccine pioneer Moderna, and is co-founder of a startup seeking to develop more affordable drugs. She helped pave the way for FDA’s breakthrough therapy designation and diversification of Genentech’s clinical trials.
Surrogate Endpoints Only Have ‘Limited’ Evidence On Cancer Survival, Review Concludes
21st Century Cures legislation also criticized in JAMA Internal Medicine editorial.
AstraZeneca Takes “Anti-Avastin” Pledge On Accelerated Approval Withdrawal
Sponsor says it would offer to remove olaparib from the market if results from ongoing SOLO-2 trial in ovarian cancer maintenance setting are “not consistent” with Phase II efficacy data upon which accelerated approval is requested.